

## Product Sales Analysis (vs PY Reported Actual)

(Sales amount includes royalty income and service income)

■ Quarterly (Q1)

(Bn JPY)	Reported			US		Japan		EUCAN		GEM*3		Ex-US	
	FY18Q1	FY19Q1	YOY	US	YOY	Japan	YOY	EUCAN	YOY	GEM*3	YOY	Ex-US	YOY
<b>GI</b>	<b>124.0</b>	<b>171.6</b>	<b>38.4%</b>	<b>101.3</b>	<b>51.7%</b>	<b>19.9</b>	<b>31.2%</b>	<b>31.9</b>	<b>14.4%</b>	<b>14.7</b>	<b>2.8%</b>	<b>3.9</b>	-
Entyvio	61.3	83.9	36.9%	59.1	40.9%	1.0	-	20.6	19.7%	3.2	47.5%		
Dexilant	17.4	15.8	-9.0%	10.9	-16.1%			1.8	8.5%	3.1	14.0%		
Pantoprazole	16.2	11.6	-28.5%	0.3	-84.9%			5.3	-26.8%	6.0	-14.4%		
Takecab-F	14.3	18.3	28.1%			18.2	27.7%			0.1	-		
Gattex/Revestive		15.1	-	13.0	-			2.0	-	0.1	-		
Pentasa		6.5	-	6.5	-								
Lialda/Mezavan *1		5.6	-	1.7	-							3.9	-
Amitiza	7.9	7.8	-0.7%	7.7	-1.4%			0.0	-88.1%	0.1	-		
Resolor/Motegrity		1.4	-	0.5	-			0.8	-	0.0	-		
Other	7.0	5.6	-19.4%	1.6	-22.9%	0.6	-27.8%	1.4	-20.3%	2.1	-12.4%		
<b>Rare Metabolic</b>		<b>48.9</b>	-	<b>16.0</b>	-	<b>0.8</b>	-	<b>10.9</b>	-	<b>8.2</b>	-	<b>12.9</b>	-
Elaprase		18.8	-	4.9	-	0.4	-	6.5	-	7.0	-		
Replagal *1		12.9	-									12.9	-
Vpriv		9.3	-	4.0	-	0.4	-	3.8	-	1.1	-		
Natpara		7.9	-	7.1	-			0.7	-	0.0	-		
<b>Rare Hematology</b>		<b>89.9</b>	-	<b>36.2</b>	-	<b>7.1</b>	-	<b>22.7</b>	-	<b>23.9</b>	-		
Advate		42.7	-	17.7	-	2.1	-	12.5	-	10.5	-		
Adynovate		16.7	-	7.6	-	3.8	-	2.4	-	2.8	-		
FEIBA *2		13.1	-	2.7	-	0.4	-	4.1	-	5.8	-		
Hemofil/Immunate/ Immunine *2		6.6	-	1.3	-			1.7	-	3.5	-		
Other PDT Products *2		0.6	-	0.0	-			0.4	-	0.2	-		
Other		10.3	-	6.9	-	0.8		1.5	-	1.1	-		
<b>Hereditary Angioedema</b>		<b>31.9</b>	-	<b>26.2</b>	-	<b>0.1</b>	-	<b>4.8</b>	-	<b>0.7</b>	-		
Firazyr		9.0	-	5.9	-	0.1	-	2.3	-	0.6	-		
Takhyro		14.5	-	13.7	-			0.8	-				
Kalbitor		1.1	-	1.1	-								
Cinryze *2		7.3	-	5.6	-			1.7	-	0.0	-		

\*1 License-out product : Regional breakdown is not available due to contract.

\*2 PDT products

\*3 GEM: Growth and Emerging Markets, which include Russia/CIS, Latin America, Asia, Middle East, Oceania and Africa

Other PDT products in Rare Hematology include Bebulin and Prothrombin.

Other in Rare Hematology include Vonvendi, Obizur, Rixubis, Agrylin/Xagrid, Recombinate, Other Hemophilia.

■Quarterly (Q1)

(Bn JPY)	Reported												
	FY18Q1	FY19Q1	YOY	US	YOY	Japan	YOY	EUCAN	YOY	GEM*3	YOY	Ex-US	YOY
<b>PDT Immunology</b>	<b>4.2</b>	<b>90.2</b>	-	<b>57.4</b>	-							<b>32.7</b>	-
Immunoglobulin *2	3.1	68.0	-	48.0	-							20.0	-
Albumin *2	0.4	16.1	-	4.3	-							11.9	-
Other *2	0.6	6.0	-	5.2	-							0.9	34.8%
<b>Oncology</b>	<b>98.9</b>	<b>106.5</b>	<b>7.6%</b>	<b>53.9</b>	<b>5.8%</b>	<b>19.9</b>	<b>9.3%</b>	<b>16.8</b>	<b>5.8%</b>	<b>11.3</b>	<b>40.5%</b>	<b>4.6</b>	<b>-22.2%</b>
Velcade *1	31.4	31.7	1.0%	28.1	7.1%							3.7	-29.4%
Leuprorelin	28.6	28.4	-0.9%	5.3	-14.5%	11.0	5.1%	7.8	-7.6%	4.2	21.4%		
Ninlaro	14.0	18.3	30.8%	12.6	13.3%	1.3	14.1%	2.7	74.1%	1.6	-		
Adcetris	11.0	12.7	16.4%			1.9	70.7%	5.6	0.7%	5.2	22.3%		
Iclusig *1	7.0	7.6	9.2%	6.7	7.0%							0.9	28.4%
Alunbrig	1.1	1.7	52.8%	1.2	12.6%			0.4	-	0.1	-		
Vectibix	5.4	5.6	3.5%			5.6	3.5%						
Other	0.5	0.4	-9.6%	0.0	-94.4%			0.3	-8.8%	0.2	2.7%		
<b>Neuroscience</b>	<b>24.3</b>	<b>111.9</b>	-	<b>87.6</b>	-	<b>10.4</b>	<b>39.6%</b>	<b>11.8</b>	-	<b>2.0</b>	-		
Vyvanse		68.8	-	59.0	-			7.9	-	1.9	-		
Trintellix	14.1	17.4	23.4%	17.4	23.4%								
Adderall XR		5.7	-	5.3	-			0.4	-				
Rozerem	5.2	5.1	-1.6%	2.3	-16.1%	2.8	14.3%			0.0	-39.4%		
Reminyl	4.5	4.8	6.5%			4.8	6.3%	0.0	-				
Intuniv		4.1	-	0.6	-	1.6	-	1.9	-	0.1	-		
Other	0.5	6.0	-	3.1	-	1.3	145.9%	1.7	-	0.0	-		
<b>Other</b>	<b>198.4</b>	<b>198.3</b>	<b>-0.1%</b>										
Azilva	19.4	20.5	5.4%			20.5	5.4%						
Nesina	14.1	14.6	3.3%	1.6	37.1%	7.6	-2.7%	2.7	4.8%	2.7	4.7%		
Uloric	14.1	12.2	-13.1%	11.9	-13.9%			0.2	-5.9%	0.2	151.7%		
Colcrys	9.2	7.2	-22.4%	7.2	-22.4%								
Enbrel	9.9	8.7	-12.1%			8.7	-12.1%						
Lotriga	8.1	8.8	8.1%			8.8	8.1%						

\*1 License-out product : Regional breakdown is not available due to contract.

\*2 PDT products

\*3 GEM: Growth and Emerging Markets, which include Russia/CIS, Latin America, Asia, Middle East, Oceania and Africa

Other in PDT Immunology include Aralast, Glassia, Kenktsu-Nonthron and others

Other in Neuroscience include Copaxone, Rasagiline, Mydayis, Buccolam, Daytrana/Equasym and Carbatrol/Equetro

**Product Sales Analysis (vs PY Reported Actual) (continued)**

(Sales amount includes royalty income and service income)

■Quarterly (Q2)

(Bn JPY)	Reported			US		Japan		EUCAN		GEM*3		Ex-US	
	FY18Q2	FY19Q2	YOY	US	YOY	Japan	YOY	EUCAN	YOY	GEM*3	YOY	Ex-US	YOY
<b>GI</b>	<b>128.1</b>	<b>169.9</b>	<b>32.7%</b>	<b>99.4</b>	<b>40.6%</b>	<b>18.3</b>	<b>33.8%</b>	<b>32.8</b>	<b>13.4%</b>	<b>15.4</b>	<b>4.4%</b>	<b>4.0</b>	-
Entyvio	67.1	84.5	26.0%	58.6	29.0%	1.5	-	21.1	10.4%	3.4	30.1%		
Dexilant	17.5	15.3	-12.8%	9.9	-21.6%			1.9	8.2%	3.5	10.7%		
Pantoprazole	14.5	12.8	-11.3%	1.0	-29.2%			5.9	-9.5%	6.0	-9.3%		
Takecab-F	13.0	16.7	28.6%			16.6	28.2%			0.1	111.5%		
Gattex/Revestive		14.1	-	12.1	-			2.0	-	0.1	-		
Pentasa		6.5	-	6.5	-								
Lialda/Mezavan *1		6.7	-	2.6	-							4.0	-
Amitiza	8.4	7.3	-13.2%	7.2	-13.7%			-0.0	-	0.1	-		
Resolor/Motegrity		1.3	-	0.5	-			0.7	-	0.0	-		
Other	7.6	4.7	-38.2%	1.0	-66.8%	0.2	-73.2%	1.3	-20.3%	2.3	-3.8%		
<b>Rare Metabolic</b>		<b>43.2</b>	-	<b>12.7</b>	-	<b>0.7</b>	-	<b>10.2</b>	-	<b>7.1</b>	-	<b>12.6</b>	-
Elaprase		16.7	-	4.8	-	0.3	-	6.1	-	5.5	-		
Replagal *1		12.6	-									12.6	-
Vpriv		9.4	-	4.0	-	0.4	-	3.4	-	1.6	-		
Natpara		4.5	-	3.8	-			0.6	-	0.0	-		
<b>Rare Hematology</b>		<b>84.8</b>	-	<b>36.1</b>	-	<b>6.9</b>	-	<b>21.0</b>	-	<b>20.8</b>	-		
Advate		40.5	-	18.0	-	2.0	-	10.9	-	9.6	-		
Adynovate		13.1	-	8.1	-	3.7	-	2.8	-	-1.4	-		
FEIBA *2		14.8	-	2.3	-	0.5	-	3.6	-	8.5	-		
Hemofil/Immunate/ Immunine *2		5.6	-	1.2	-			1.5	-	2.9	-		
Other PDT Products *2		0.5	-	-0.0	-			0.4	-	0.1	-		
Other		10.3	-	6.6	-	0.7	-	1.9	-	1.2	-		
<b>Hereditary Angioedema</b>		<b>28.5</b>	-	<b>22.5</b>	-	<b>0.2</b>	-	<b>4.9</b>	-	<b>0.9</b>	-		
Firazyr		6.3	-	3.0	-	0.2	-	2.3	-	0.8	-		
Takhyro		16.2	-	15.2	-			1.0	-	0.0	-		
Kalbitor		1.3	-	1.3	-			0.0	-		-		
Cinryze *2		4.7	-	3.0	-			1.6	-	0.1	-		

\*1 License-out product : Regional breakdown is not available due to contract.

\*2 PDT products

\*3 GEM: Growth and Emerging Markets, which include Russia/CIS, Latin America, Asia, Middle East, Oceania and Africa

Other PDT products in Rare Hematology include Bebulin and Prothrombin.

Other in Rare Hematology include Vonvendi, Obizur, Rixubis, Agrylin/Xagrid, Recombinate, Other Hemophilia.

■Quarterly (Q2)

(Bn JPY)	Reported												
	FY18Q2	FY19Q2	YOY	US	YOY	Japan	YOY	EUCAN	YOY	GEM*3	YOY	Ex-US	YOY
<b>PDT Immunology</b>	<b>3.8</b>	<b>101.5</b>	-	<b>69.7</b>	-							<b>31.8</b>	-
Immunoglobulin *2	2.8	78.5	-	61.6	-							16.9	-
Albumin *2	0.4	17.9	-	3.6	-							14.3	-
Other *2	0.6	5.1	-	4.4	-							0.7	15.7%
<b>Oncology</b>	<b>99.5</b>	<b>108.4</b>	<b>8.9%</b>	<b>57.4</b>	<b>12.0%</b>	<b>18.8</b>	<b>12.5%</b>	<b>16.8</b>	<b>6.4%</b>	<b>11.3</b>	<b>31.2%</b>	<b>3.7</b>	<b>-48.2%</b>
Velcade *1	33.5	31.9	-4.7%	29.1	7.4%							2.8	-55.9%
Leuprorelin	26.5	28.3	6.7%	7.1	43.9%	9.6	-0.5%	7.3	-12.7%	4.3	20.2%		
Ninlaro	15.4	20.0	29.7%	13.9	19.1%	1.2	31.3%	2.8	46.7%	2.1	130.7%		
Adcetris	10.1	13.0	28.3%			2.0	90.2%	6.0	15.2%	4.6	19.2%		
Iclusig *1	7.2	7.0	-1.7%	6.1	-4.0%							0.9	17.7%
Alunbrig	1.2	1.7	44.2%	1.2	4.2%			0.4	-	0.1	-		
Vectibix	5.1	6.0	17.3%			6.0	17.3%						
Other	0.5	0.5	-14.4%	-0.0	-			0.3	-3.7%	0.2	-21.7%		
<b>Neuroscience</b>	<b>22.1</b>	<b>102.0</b>	-	<b>79.4</b>	-	<b>10.2</b>	<b>57.8%</b>	<b>11.1</b>	-	<b>1.3</b>	-		
Vyvanse		62.7	-	54.2	-			7.2	-	1.3	-		
Trintellix	13.0	17.2	32.2%	17.2	32.2%								
Adderall XR		4.9	-	4.5	-			0.5	-				
Rozerem	4.9	3.6	-27.4%	0.8	-69.3%	2.7	22.4%			0.0	13.8%		
Reminyl	3.9	4.2	8.4%			4.2	8.0%	0.0	-				
Intuniv		4.0	-	0.2	-	2.0	-	1.7	-	0.0	-		
Other	0.3	5.3	-	2.5	-	1.2	-	1.7	-	0.0	-		
<b>Other</b>	<b>177.2</b>	<b>172.7</b>	<b>-2.5%</b>										
Azilva	15.8	18.2	15.5%			18.2	15.5%						
Nesina	12.7	14.0	10.3%	1.6	-2.1%	6.7	3.6%	2.6	4.3%	3.1	47.9%		
Uloric	12.4	1.8	-85.3%	1.6	-86.9%			0.1	-37.1%	0.1	18.3%		
Colcrys	7.1	6.0	-15.8%	6.0	-15.8%								
Enbrel	8.2	7.2	-11.6%			7.2	-11.6%						
Lotriga	7.1	7.2	1.2%			7.2	1.2%						

\*1 License-out product : Regional breakdown is not available due to contract.

\*2 PDT products

\*3 GEM: Growth and Emerging Markets, which include Russia/CIS, Latin America, Asia, Middle East, Oceania and Africa

Other in PDT Immunology include Aralast, Glassia, Kenktsu-Nonthron and others

Other in Neuroscience include Copaxone, Rasagiline, Mydayis, Buccolam, Daytrana/Equasym and Carbatrol/Equetro

## Product Sales Analysis (vs FY2018 Pro-forma)

Pro-forma includes 12-month (April 2018 – March 2019) revenue of legacy Shire as if the acquisition of Shire had occurred on April 1, 2018. This pro-forma revenue may not represent what sales would have been had the acquisition of Shire had occurred on April 1, 2018.

(Bn JPY)	FY18 Reported Pro-forma*2				FY19 Reported (Financial Reported Base)															
	Q1	Q2	Q3	Q4	YOY			YOY				YOY				YOY				
					Q1	Reported	Underlying	Q2	Reported	Underlying	YTD Underlying	Q3	Reported	Underlying	YTD Underlying	Q4	Reported	Underlying	YTD Underlying	
<b>GI</b>	<b>159.4</b>	<b>160.4</b>	<b>177.1</b>	<b>146.5</b>	<b>171.6</b>	<b>7.7%</b>	<b>7.9%</b>	<b>169.9</b>	<b>5.9%</b>	<b>9.9%</b>	<b>8.9%</b>									
Entyvio	61.3	67.1	72.6	68.2	83.9	36.9%	36.8%	84.5	26.0%	31.3%	33.9%									
Dexilant	17.4	17.5	20.0	14.3	15.8	-9.0%	-9.4%	15.3	-12.8%	-9.3%	-9.4%									
Pantoprazole	16.2	14.5	16.2	14.7	11.6	-28.5%	-25.0%	12.8	-11.3%	-6.0%	-16.0%									
Takecab-F	14.3	13.0	17.1	13.9	18.3	28.1%	28.1%	16.7	28.6%	28.6%	28.3%									
Gattex/Revestive	14.5	10.8	13.9	12.8	15.1	4.5%	3.3%	14.1	31.2%	35.9%	17.0%									
Pentasa	8.4	7.3	9.4	4.7	6.5	-22.4%	-23.7%	6.5	-11.1%	-8.4%	-16.7%									
Lialda/Mezavant	11.7	13.6	11.2	3.3	5.6	-52.5%	-51.7%	6.7	-50.9%	-48.5%	-50.0%									
Amitiza	7.9	8.4	9.6	7.1	7.8	-0.7%	-3.0%	7.3	-13.2%	-10.5%	-6.8%									
Resolor/Motegrity	0.7	0.7	1.8	0.7	1.4	85.1%	103.8%	1.3	94.4%	91.9%	97.7%									
Other	7.0	7.6	5.2	6.8	5.6	-19.4%	-18.4%	4.7	-38.2%	-35.7%	-27.4%									
<b>Rare Metabolic</b>	<b>49.4</b>	<b>47.9</b>	<b>51.0</b>	<b>42.3</b>	<b>48.9</b>	<b>-1.2%</b>	<b>3.9%</b>	<b>43.2</b>	<b>-9.8%</b>	<b>-2.1%</b>	<b>1.0%</b>									
Elaprase	19.1	18.9	19.1	15.1	18.8	-1.4%	3.6%	16.7	-11.7%	-4.8%	-0.6%									
Replagal	13.6	13.6	13.4	11.4	12.9	-5.3%	3.5%	12.6	-7.8%	2.7%	3.1%									
Vpriv	9.7	9.7	10.7	8.7	9.3	-4.6%	0.6%	9.4	-3.0%	5.7%	3.1%									
Natpara	7.0	5.7	7.9	7.1	7.9	11.8%	10.2%	4.5	-20.1%	-17.9%	-2.2%									
<b>Rare Hematology</b>	<b>105.2</b>	<b>102.1</b>	<b>107.6</b>	<b>66.7</b>	<b>89.9</b>	<b>-14.5%</b>	<b>-12.6%</b>	<b>84.8</b>	<b>-17.0%</b>	<b>-12.7%</b>	<b>-12.7%</b>									
Advate	53.7	49.5	53.8	32.1	42.7	-20.4%	-18.1%	40.5	-18.1%	-13.5%	-15.9%									
Adynovate	13.2	15.4	15.4	10.7	16.7	26.4%	25.9%	13.1	-15.1%	-12.3%	5.4%									
FEIBA *1	21.5	17.2	16.3	9.6	13.1	-39.4%	-36.8%	14.8	-13.9%	-9.2%	-24.4%									
Hemofil/Immunate/ Immune *1	5.5	5.7	7.2	5.5	6.6	18.3%	23.0%	5.6	-2.5%	3.4%	13.0%									
Other PDT Products *1	1.0	0.6	0.8	0.5	0.6	-34.6%	-32.3%	0.5	-18.5%	-15.0%	-25.4%									
Other	10.2	13.7	14.1	8.3	10.3	0.8%	-1.1%	10.3	-24.5%	-21.6%	-12.7%									
<b>Hereditary Angioedema</b>	<b>39.7</b>	<b>36.5</b>	<b>32.8</b>	<b>20.4</b>	<b>31.9</b>	<b>-19.8%</b>	<b>-19.9%</b>	<b>28.5</b>	<b>-22.0%</b>	<b>-18.4%</b>	<b>-19.2%</b>									
Firazyr	23.0	15.6	24.4	6.4	9.0	-61.0%	-60.4%	6.3	-59.6%	-56.5%	-58.8%									
Takhzyro		5.7	1.2	9.7	14.5	-	-	16.2	184.5%	194.4%	-									
Kalbitor	1.9	2.3	2.1	1.2	1.1	-41.5%	-42.7%	1.3	-43.6%	-41.8%	-42.2%									
Cinryze *1	14.8	13.0	5.1	3.1	7.3	-50.7%	-50.8%	4.7	-63.8%	-62.0%	-56.0%									

\*1 PDT products

\*2 Pro-forma based product sales and therapeutic area sales which include Legacy Shire's products. Shire's 12 months (April 2018-March 2019) revenue under U.S. GAAP, excluding the oncology business which was divested in August 2018, converted to JPY using FY2018 actual rate for the period.

Other PDT products in Rare Hematology include Bebulin and Prothrombin.

Other in Rare Hematology include Vonvendi, Obizur, Rixubis, Agrylin/Xagrid, Recombinate, Other Hemophilia.

(Bn JPY)	FY18 Reported Pro-forma*2				FY19 Reported (Financial Reported Base)														
	Q1	Q2	Q3	Q4	YOY			YOY			YTD Underlying	YOY			YTD Underlying	YOY			YTD Underlying
					Q1	Reported	Underlying	Q2	Reported	Underlying		Q3	Reported	Underlying		Q4	Reported	Underlying	
<b>PDT Immunology</b>	<b>89.1</b>	<b>100.0</b>	<b>101.9</b>	<b>81.0</b>	<b>90.2</b>	<b>1.2%</b>	<b>1.6%</b>	<b>101.5</b>	<b>1.5%</b>	<b>5.3%</b>	<b>3.6%</b>								
Immunoglobulin *1	69.5	75.5	77.4	64.3	68.0	-2.2%	-1.9%	78.5	4.0%	7.6%	3.0%								
Albumin *1	12.9	17.3	17.0	11.0	16.1	25.6%	27.5%	17.9	3.8%	9.0%	16.9%								
Other *1	6.7	7.2	7.5	5.6	6.0	-10.1%	-11.3%	5.1	-29.3%	-27.3%	-19.6%								
<b>Oncology</b>	<b>98.9</b>	<b>99.5</b>	<b>108.2</b>	<b>92.8</b>	<b>106.5</b>	<b>7.6%</b>	<b>8.1%</b>	<b>108.4</b>	<b>8.9%</b>	<b>12.9%</b>	<b>10.5%</b>								
Velcade	31.4	33.5	35.4	27.5	31.7	1.0%	-1.3%	31.9	-4.7%	-1.7%	-1.5%								
Leuprorelin	28.6	26.5	29.5	25.4	28.4	-0.9%	0.6%	28.3	6.7%	9.4%	4.9%								
Ninlaro	14.0	15.4	17.1	15.7	18.3	30.8%	29.8%	20.0	29.7%	35.4%	32.7%								
Adcetris	11.0	10.1	10.9	10.9	12.7	16.4%	26.6%	13.0	28.3%	39.0%	32.7%								
Iclusig	7.0	7.2	7.4	7.1	7.6	9.2%	6.7%	7.0	-1.7%	1.3%	4.0%								
Alunbrig	1.1	1.2	1.5	1.4	1.7	52.8%	51.1%	1.7	44.2%	50.2%	50.7%								
Vectibix	5.4	5.1	5.7	4.3	5.6	3.5%	3.5%	6.0	17.3%	17.3%	10.2%								
Other	0.5	0.5	0.6	0.4	0.4	-9.6%	2.5%	0.5	-14.4%	-3.9%	-0.9%								
<b>Neuroscience</b>	<b>100.8</b>	<b>104.2</b>	<b>118.4</b>	<b>81.0</b>	<b>111.9</b>	<b>11.1%</b>	<b>10.1%</b>	<b>102.0</b>	<b>-2.2%</b>	<b>1.1%</b>	<b>5.6%</b>								
Vyvanse	60.4	66.0	71.0	49.4	68.8	13.9%	12.8%	62.7	-5.0%	-1.5%	5.4%								
Trintellix	14.1	13.0	17.5	12.9	17.4	23.4%	20.7%	17.2	32.2%	36.2%	28.1%								
Adderall XR	8.8	8.6	11.3	5.4	5.7	-35.6%	-36.6%	4.9	-42.5%	-40.9%	-38.7%								
Rozerem	5.2	4.9	4.8	4.2	5.1	-1.6%	-2.8%	3.6	-27.4%	-26.9%	-14.5%								
Reminyl	5.0	4.3	5.3	3.7	4.8	-4.4%	-4.7%	4.2	-0.5%	-0.1%	-2.6%								
Intuniv	2.7	2.9	2.9	1.3	4.1	53.3%	60.2%	4.0	34.2%	41.9%	50.5%								
Other	4.5	4.5	5.6	4.0	6.0	33.4%	34.6%	5.4	18.3%	22.8%	28.7%								
<b>Other</b>																			
Azilva	19.4	15.8	20.5	15.0	20.5	5.4%	5.4%	18.2	15.5%	15.5%	9.9%								
Nesina	14.1	12.7	15.6	12.3	14.6	3.3%	5.0%	14.0	10.3%	13.6%	9.1%								
Uloric	14.1	12.4	14.0	10.6	12.2	-13.1%	-15.0%	1.8	-85.3%	-84.8%	-47.2%								
Colcrys	9.2	7.1	7.3	6.4	7.2	-22.4%	-24.1%	6.0	-15.8%	-13.3%	-19.5%								
Enbrel	9.9	8.2	9.8	7.3	8.7	-12.1%	-12.1%	7.2	-11.6%	-11.6%	-11.9%								
Lotriga	8.1	7.1	9.0	6.6	8.8	8.1%	8.1%	7.2	1.2%	1.2%	4.9%								

\*1 PDT products

\*2 Pro-forma based product sales and therapeutic area sales which include Legacy Shire's products. Shire's 12 months (April 2018-March 2019) revenue under U.S. GAAP, excluding the oncology business which was divested in August 2018, converted to JPY using FY2018 actual rate for the period.

Other in PDT Immunology include Aralast, Glassia, Kenktsu-Nonthron and others

Other in Neuroscience include Copaxone, Rasagiline, Mydayis, Buccolam, Daytrana/Equasym and Carbatrol/Equetro